SRTS - yeah, i don't like two worthless pr's within a couple of days of earnings. Seems very suspect. I hope the company gets back on track, but tough to believe them when they're trying to make minutiae sound like a big deal. In fact, their "collaboration" announced a couple of days ago sounds like it will increase costs in the short term due to increased regulation:
"Under the collaboration, CureRays will provide Sensus’ dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened. In addition, CureRays will research new indications for Sensus’ superficial radiotherapy (SRT and IG-SRT), including inflammatory diseases."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.